NCT05104619 Spectroscopic Analysis of Tongue Tumor Samples.
| NCT ID | NCT05104619 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Mass Spectroscopy |
| Study Type | OBSERVATIONAL |
| Enrollment | 33 participants |
| Start Date | 2021-03-10 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 33 participants in total. It began in 2021-03-10 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In squamous cell carcinoma of the tongue, complete surgical resection of the tumor generally represents the primary treatment strategy. Among factors determining the disease prognostic, the surgical margins status is essential for the continued management of the patient, with or without complementary therapies. Generally, surgical margins are defined using visual and tactile elements. Unfortunately, in 15 to 30 percent of cases, they are defined as positive after histopathological examination, on average 5 to 7 days post-surgery. Techniques have recently been developed to analyze the cancerous and non-cancerous nature of tissues, using the spectral properties of tumor cells. SpiderMass™ is an instrument equipped with a probe for tissue micro-sampling and real-time molecular profile analysis. It is thus ultimately a tool for anatomopathological decision support, for diagnosis and prognosis of the disease. Used in the operating room, SpiderMass™ could also become an innovative surgical tool to precisely define cancerous areas in situ and the margins status in intraoperative conditions. Based on the principle of artificial intelligence, the SpiderMass™ machine must initially learn to recognize pathological tissues versus healthy. This project aims to accomplish this first phase of machine learning for squamous cell carcinoma of the tongue.
Eligibility Criteria
Inclusion Criteria: * age : 18 years and older * squamous cell carcinoma of the tongue * surgical resection as first-line treatment * tumor classification T1 to T4. Exclusion Criteria: * metastatic disease * neoadjuvant therapies
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05104619 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mass Spectroscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05104619 currently recruiting?
Yes, NCT05104619 is actively recruiting participants. Contact the research team at attencourt.christophe@chu-amiens.fr for enrollment information.
Where is the NCT05104619 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT05104619 clinical trial?
NCT05104619 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 33 participants.